Loading
HT
HLS Therapeutics Inc. Stock: price and insider trades · Canada
CA·Mcap CA$126.5M
HLS Therapeutics Inc.: what insiders have been doing
Every trade that managers of HLS Therapeutics Inc. disclose to SEDI is tracked on this page. Over the twelve months to 21 October 2026, 154 filings were filed, from 8 insiders.
The flow runs one way only: 3 insiders bought (6 purchases totalling €28k) and nobody sold on the market. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 3 senior executives among the declarants. One trade stands out by size: a purchase of €11k from Hanna, John Gordon, disclosed on 17 June 2026.
The last insider purchase was made public on 8 September 2026, 42 days ago. Between a trade and the moment it shows up on SEDI, the median delay is 28 days. The shorter that gap, the sooner other investors can see what insiders have done.
Across the 2,121 companies tracked on its exchange, the median is 11 filings; at 154 filings, this issuer sits above that mark. Since 2026, the database holds 6 purchases and no sales by insiders of the company.
Source: insider filings from SEDI. Past trades are no guide to future returns.
Insider Decl.
154
Thresholds
n/a
Buy Volume
€28,209
6 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleCraig Millian3 buys
John Gordon Hanna2 buys
Ryan Christopher Lennox1 buy
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 16,294 of 26,281 companies
44.0
score / 100
Value50
Quality38
FCF yld12%
Earn yld-9.8%
EV/EBITDA11.0x
ROE-14%
Gross mgn82%
Net mgn-22%
Debt/EBITDA3.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
CA$4.09
Analyst consensus
4 analysts1.50/5
CA$4.55Target CA$7.52(+84%)CA$12.30
Income statement
RevenueCA$55.5M
Gross profitCA$45.4M82% margin
EBITDACA$16M29% margin
Net income-CA$12.4M-15.2% margin
Valuation
PER (forward)-58.4x
P/Book1.6x
Beta0.76
Balance sheet & cash
Market capCA$126.5M
Total debtCA$49.8M
Free Cash FlowCA$15.4M
Debt / Equity76%
Profitability & ownership
ROE-14.1%
ROA-2.0%
% insiders0.6%
% institutions44.9%
Last declaration on 5 October 2026
Declarations154 total
1,000 sharesCommon SharesTSXSEDI:4786860
1,000 shares@ CA$4.000.0033% mcap0.1% of flowCommon SharesTSXSEDI:4786857
2,000 sharesCommon SharesTSXSEDI:4786853
2,000 shares@ CA$4.000.0066% mcap0.2% of flowCommon SharesTSXSEDI:4786852
2,000 sharesCommon SharesTSXSEDI:4786849
2,000 shares@ CA$3.9920.0066% mcap0.2% of flowCommon SharesTSXSEDI:4786847
2,000 sharesCommon SharesTSXSEDI:4786845
2,000 shares@ CA$3.9540.0065% mcap0.2% of flowCommon SharesTSXSEDI:4786844
2,000 sharesCommon SharesTSXSEDI:4786840
2,000 shares@ CA$4.000.0066% mcap0.2% of flowCommon SharesTSXSEDI:4786839
2,000 sharesCommon SharesTSXSEDI:4786837
2,000 shares@ CA$3.980.0066% mcap0.2% of flowCommon SharesTSXSEDI:4786835
2,000 sharesCommon SharesTSXSEDI:4786831
2,000 shares@ CA$3.970.0066% mcap0.2% of flowCommon SharesTSXSEDI:4786829
2,080 sharesCommon SharesTSXSEDI:4786826
2,080 shares@ CA$3.9940.0069% mcap0.2% of flowCommon SharesTSXSEDI:4786824
2,000 sharesCommon SharesTSXSEDI:4786822
2,000 shares@ CA$4.0050.0067% mcap0.2% of flowCommon SharesTSXSEDI:4786819
2,000 sharesCommon SharesTSXSEDI:4786817
2,000 shares@ CA$4.0290.0067% mcap0.2% of flowCommon SharesTSXSEDI:4786814
2,000 sharesCommon SharesTSXSEDI:4786811
2,000 shares@ CA$4.050.0067% mcap0.2% of flowCommon SharesTSXSEDI:4786809
2,000 sharesCommon SharesTSXSEDI:4786807
2,000 shares@ CA$4.1450.0069% mcap0.2% of flowCommon SharesTSXSEDI:4786806
101,000 sharesCommon SharesTSXSEDI:4786803
25 of 154 declarations
About HLS Therapeutics Inc.
HLS Therapeutics Inc. is a Canadian pharmaceutical company focused on the development and commercialization of treatments for chronic diseases. It is listed on the Toronto Stock Exchange under the symbol HLS.
